In the first study of its kind, mosquitoes captured high above Mali and Ghana were found to be infected with arboviruses, ...
Butantan-DV is the world's first single-dose dengue vaccine and will initially be administered to people aged 12 to 59. Learn more.
Takeda teams up with Biological E. to boost TAK-003 manufacturing Biological E. to scale up capacity, targeting 50 million doses annually Hyderabad chosen as the site for vaccine production, ...
A newly confirmed travel-related dengue case on Oʻahu brings Hawai‘i’s 2025 total to 14. Health officials say there is still ...
Takeda and Biological E Limited have partnered to manufacture up to 50 million doses per year of the dengue vaccine QDENGA, with the goal of delivering 100 million doses by 2030. The collaboration ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of ...
Five more people have died of dengue fever in Bangladesh and 1,139 patients have been hospitalised with the disease in the ...
In light of the increasing rate of dengue infections throughout the world despite vector-control measures, several dengue vaccine candidates are in development. In a phase 3 efficacy trial of a ...
Another two patients have died of dengue fever while undergoing treatment at Sher-e-Bangla Medical College Hospital in Barishal. Shyamal Krishna Mondal, director of the Directorate General of Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback